% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gkika:300324,
      author       = {E. Gkika$^*$ and E. Firat$^*$ and S. Adebahr$^*$ and E.
                      Graf and I. Popp$^*$ and A. Eichhorst$^*$ and G.
                      Radicioni$^*$ and S. S. Lo$^*$ and S. K. B. Spohn$^*$ and U.
                      Nestle and N. H. Nicolay$^*$ and G. Niedermann$^*$ and A.-L.
                      Grosu$^*$ and D. G. Duda},
      title        = {{A} prospective study of immune responses in patients with
                      lung metastases treated with stereotactic body radiotherapy
                      with or without concurrent systemic treatment.},
      journal      = {Radiotherapy and oncology},
      volume       = {207},
      issn         = {0167-8140},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-00770},
      pages        = {110889},
      year         = {2025},
      note         = {Volume 207, June 2025, 110889},
      abstract     = {We evaluated the longitudinal effects of stereotactic body
                      radiotherapy (SBRT) on circulating immune cells.Patients
                      with oligometastatic/oligoprogressive pulmonary lesions were
                      treated with ablative SBRT with (cSBRT) or without (SBRT
                      group) concurrent systemic treatment (chemotherapy or immune
                      checkpoint blockade, ICB) using different fractionation
                      regimes. Immunoprofiling of peripheral blood cells was
                      performed at baseline, during, and at the end of SBRT, and
                      during the first (FU1) and second follow-ups (FU2). The
                      primary endpoint was the increase in CD8+ T cells at FU1
                      compared to baseline.The study accrued 100 patients, 80 with
                      evaluable samples. At FU1 12 $\%$ and 20 $\%$ of the
                      patients experienced an increase in CD8+ T-cell counts in
                      the SBRT and cSBRT groups, respectively. With a median
                      follow-up of 30 months, the median OS was 30 months in the
                      SBRT group and 53 months for the cSBRT group. Lower doses
                      per fraction led to a significant increase in the proportion
                      of proliferating CD4+ and CD8+ T cells. The effect size of
                      standardized changes from baseline in proliferating T cells
                      was considerably more significant in the SBRT group. The
                      increased T-cell proliferation was prominent at the end of
                      treatment and maintained at FU1 (SBRT, cSBRT) and FU2
                      (SBRT). The addition of ICBs did not lead to an augmentation
                      of this systemic immunomodulatory effect.In
                      oligometastatic/oligoprogressive disease, the optimal dose
                      and fractionation for ablative SBRT might be with less than
                      10 Gy per fraction and the optimal timing of systemic
                      treatment may be post-SBRT to leverage the immune-modulating
                      effects of SBRT.},
      keywords     = {Immune modulation (Other) / Immunomodulatory effects
                      (Other) / Lung cancer (Other) / Lung metastases (Other) /
                      SBRT (Other) / Stereotactic body radiotherapy (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40209858},
      doi          = {10.1016/j.radonc.2025.110889},
      url          = {https://inrepo02.dkfz.de/record/300324},
}